Status:

ACTIVE_NOT_RECRUITING

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Lead Sponsor:

BeOne Medicines

Conditions:

CLL

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

Detailed Description

Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, wei...

Eligibility Criteria

Inclusion

  • Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
  • Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
  • Measurable disease by Computer Tomography/Magnetic Resonance Imaging
  • Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \< 3.0 x ULN
  • Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute

Exclusion

  • Previous systemic treatment for CLL
  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  • Known central nervous system involvement
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • Uncontrolled hypertension
  • Note: Other protocol defined criteria may apply

Key Trial Info

Start Date :

November 11 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2032

Estimated Enrollment :

652 Patients enrolled

Trial Details

Trial ID

NCT06073821

Start Date

November 11 2023

End Date

December 1 2032

Last Update

January 6 2026

Active Locations (203)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 51 (203 locations)

1

Alaska Oncology and Hematology, Llc

Anchorage, Alaska, United States, 99508-2974

2

City of Hope National Medical Center

Duarte, California, United States, 91010-3012

3

University of California San Diego (Ucsd) Moores Cancer Center

La Jolla, California, United States, 92093-1503

4

Valkyrie Clinical Trials

Los Angeles, California, United States, 90067-2011